Pharmaceutical - Women's Health, Research

Filter

Current filters:

Women's HealthResearch

Popular Filters

Ph III trial for AbbVie’s elagolix meets endpoints

08-01-2015

US pharma major AbbVie and partner Neurocrine Biosciences have announced positive top-line results from…

AbbVieelagolixNeurocrine BiosciencesPharmaceuticalResearchWomen's Health

Milestone from Gedeon Richter as Palatin initiates Ph III bremelanotide study

Milestone from Gedeon Richter as Palatin initiates Ph III bremelanotide study

31-12-2014

US biopharma company Palatin Technologies says it has started its bremelanotide pivotal registration…

bremelanotideGedeon RichterLicensingPalatin TechnologiesPharmaceuticalResearchWomen's Health

Merck’s odanacatib succeeds in Ph III osteoporosis trial

Merck’s odanacatib succeeds in Ph III osteoporosis trial

16-09-2014

US pharma giant Merck & Co has announced positive data from the pivotal Phase III fracture outcomes study…

Anti-Arthritics/RheumaticsMerck & CoodanacatibPharmaceuticalResearchWomen's Health

Hera Therapeutics’ HTI-1968 shuts down HPV that causes most cervical cancer

Hera Therapeutics’ HTI-1968 shuts down HPV that causes most cervical cancer

23-08-2014

Research presented at the 29th Annual International Papillomavirus Conference shows that a therapy being…

Anti-viralsHera Therapeuticshti-1968PharmaceuticalResearchWomen's Health

Ferring and Roche collaborate to develop personalized infertility treatment

Ferring and Roche collaborate to develop personalized infertility treatment

25-06-2014

Privately-held Switzerland-headquartered Ferring Pharmaceuticals and Swiss drug major Roche have entered…

Ferring PharmaceuticalsPharmaceuticalReproductiveResearchRocheWomen's Health

Merck, Ferring and WHO working together to prevent excessive bleeding in women after childbirth

Merck, Ferring and WHO working together to prevent excessive bleeding in women after childbirth

06-04-2014

US pharma giant Merck & Co and privately-held Switzerland-headquartered Ferring Pharmaceuticals have…

carbetocinFerring PharmaceuticalsGlobalMarkets & MarketingMerck & CoPharmaceuticalResearchWomen's Health

No increase in risk of autism from taking SSRIs in pregnancy

25-11-2013

New research cannot establish a close connection between the use of antidepressant medication - the so-called…

NeurologicalPharmaceuticalResearchWomen's Health

FDA approves Bayer’s Adempas; firm accelerates drug candidates

FDA approves Bayer’s Adempas; firm accelerates drug candidates

09-10-2013

The US Food and Drug Administration late yesterday approved Adempas (riociguat), developed by German…

AdempasBayerCardio-vascularcopanlisibfinerenoneNorth AmericaOncologyPharmaceuticalRegulationResearchRespiratory and PulmonaryWomen's Health

Aspirin may lower risk of melanoma, researchers suggest

11-03-2013

A new study has found that women who take aspirin have a reduced risk of developing melanoma - and that…

AspirinOncologyPharmaceuticalResearchWomen's Health

New data on Amgen's Prolia and Merck & Co's odanacatib presented at ASBMR meeting

15-10-2012

Amgen (Nasdaq: AMGN), the world's largest biotech firm, has presented data from several Prolia (denosumab)…

AmgenAnti-Arthritics/RheumaticsBiotechnologyMerck & CoodanacatibPharmaceuticalProliaResearchWomen's Health

Depomed says BREEZE 3 data for Serada shows benefits for hot flashes

04-10-2012

USA-based Depomed (Nasdaq: DEPO) is presenting two abstracts from its Phase III clinical trial, BREEZE…

DepomedMetabolicsPharmaceuticalResearchSeradaWomen's Health

Depomed to file NDA for Serada; with Valeant sues Watson over Glumetza

20-04-2012

US drugmaker Depomed (Nasdaq: DEPO) says that it has completed a Type B pre-New Drug Application meeting…

DepomedDiabetesGenericsGlumetzaNorth AmericaPatentsPharmaceuticalRegulationResearchSeradaValeant PharmaceuticalsWatson PharmaceuticalsWomen's Health

Back to top